SG11201505928YA - 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors - Google Patents

2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

Info

Publication number: SG11201505928YA
Authority: SG; Singapore
Prior art keywords: phosphoinositide; quinazolin; pyrazolo; pyrimidin; hydroxyphenyl
Prior art date: 2013-03-15

Application number

SG11201505928YA

Inventor

Stuart Thomas Onions

Alex Herman Copmans

Rudy Laurent Maria Broeckx

Alun John Smith

David Michel Adrien Taddei

Original Assignee

Respivert Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2013-03-15

Filing date

2014-03-14

Publication date

2015-09-29

2014-03-14 Application filed by Respivert Ltd filed Critical Respivert Ltd

2015-09-29 Publication of SG11201505928YA publication Critical patent/SG11201505928YA/en

Links

DNFJCBFEJDRXTO-UHFFFAOYSA-N 2-[[4-amino-3-(3-fluoro-5-hydroxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]methyl]-3-[[2-(trifluoromethyl)phenyl]methyl]quinazolin-4-one Chemical class N1=C(C=2C=C(F)C=C(O)C=2)C=2C(N)=NC=NC=2N1CC1=NC2=CC=CC=C2C(=O)N1CC1=CC=CC=C1C(F)(F)F DNFJCBFEJDRXTO-UHFFFAOYSA-N 0.000 title 1
239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 title 1
229940043441 phosphoinositide 3-kinase inhibitor Drugs 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pulmonology (AREA)
Epidemiology (AREA)
Physical Education & Sports Medicine (AREA)
Oncology (AREA)
Ophthalmology & Optometry (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Pain & Pain Management (AREA)
Communicable Diseases (AREA)
Otolaryngology (AREA)
Virology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

SG11201505928YA 2013-03-15 2014-03-14 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors SG11201505928YA (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP13275070		2013-03-15
EP13193372		2013-11-18
PCT/GB2014/050770 WO2014140597A1 (en)	2013-03-15	2014-03-14	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

Publications (1)

Publication Number	Publication Date
SG11201505928YA true SG11201505928YA (en)	2015-09-29

Family

ID=50349644

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SG11201505928YA SG11201505928YA (en)	2013-03-15	2014-03-14	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors

Country Status (23)

Country	Link
US (2)	US9745306B2 (en)
EP (1)	EP2970293B1 (en)
JP (1)	JP6353856B2 (en)
KR (1)	KR20150127607A (en)
CN (1)	CN105229007B (en)
AU (1)	AU2014229768B2 (en)
BR (1)	BR112015019754A8 (en)
CA (1)	CA2899812A1 (en)
CL (1)	CL2015002606A1 (en)
EA (1)	EA029218B1 (en)
ES (1)	ES2640624T3 (en)
GT (1)	GT201500218A (en)
IL (1)	IL240061A0 (en)
JO (1)	JO3279B1 (en)
MX (1)	MX2015012091A (en)
NI (1)	NI201500134A (en)
PE (1)	PE20151653A1 (en)
PH (1)	PH12015501836A1 (en)
SG (1)	SG11201505928YA (en)
TW (1)	TW201522341A (en)
UA (1)	UA116002C2 (en)
UY (1)	UY35446A (en)
WO (1)	WO2014140597A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN101945869B (en)	2007-12-19	2014-06-18	癌症研究技术有限公司	Pyrido[2,3-B]pyrazine-8-substituted compounds and uses thereof
US8815896B2 (en)	2010-02-01	2014-08-26	The Institute Of Cancer Research: Royal Cancer Hospital	1-(5-tert-butyl-2-phenyl-2H-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1H-imidazo[4,5-B]pyridin-7-yloxy)-phenyl]-urea and related compounds and their use in therapy
WO2014110574A1 (en)	2013-01-14	2014-07-17	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors
RS60244B1 (en)	2013-01-15	2020-06-30	Incyte Holdings Corp	Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors
WO2015027124A1 (en)	2013-08-23	2015-02-26	Incyte Corporation	Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors
GB201320729D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Therapeutic compounds and their use
GB201320732D0 (en)	2013-11-25	2014-01-08	Cancer Rec Tech Ltd	Methods of chemical synthesis
MX2017000208A (en)	2014-07-04	2017-05-01	Lupin Ltd	Quinolizinone derivatives as pi3k inhibitors.
WO2016010897A1 (en)	2014-07-14	2016-01-21	Incyte Corporation	Bicyclic heteroaromatic carboxamide compounds useful as pim kinase inhibitors
US9580418B2 (en)	2014-07-14	2017-02-28	Incyte Corporation	Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors
US9540347B2 (en)	2015-05-29	2017-01-10	Incyte Corporation	Pyridineamine compounds useful as Pim kinase inhibitors
AR105967A1 (en)	2015-09-09	2017-11-29	Incyte Corp	SALTS OF A PIM QUINASA INHIBITOR
US9920032B2 (en)	2015-10-02	2018-03-20	Incyte Corporation	Heterocyclic compounds useful as pim kinase inhibitors
AR113922A1 (en)	2017-12-08	2020-07-01	Incyte Corp	LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2369895C (en)	1999-01-11	2010-12-21	Princeton University	High affinity inhibitors for target validation and uses thereof
KR100785363B1 (en)	2000-04-25	2007-12-18	이코스 코포레이션	Inhibitors of human phosphatidyl-inositol 3-kinase delta
US6667300B2 (en)	2000-04-25	2003-12-23	Icos Corporation	Inhibitors of human phosphatidylinositol 3-kinase delta
US6608053B2 (en)	2000-04-27	2003-08-19	Yamanouchi Pharmaceutical Co., Ltd.	Fused heteroaryl derivatives
KR100774855B1 (en)	2000-04-27	2007-11-08	아스텔라스세이야쿠 가부시키가이샤	Condensed heteroaryl derivatives
EP1217000A1 (en)	2000-12-23	2002-06-26	Aventis Pharma Deutschland GmbH	Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en)	2001-07-13	2003-01-23	Virtual Drug Development, Inc.	Nad synthetase inhibitors and uses thereof
AU2002317377A1 (en)	2001-07-20	2003-03-03	Cancer Research Technology Limited	Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
AU2003301662A1 (en)	2002-10-21	2004-05-13	Bristol-Myers Squibb Company	Quinazolinones and derivatives thereof as factor xa inhibitors
JP4736043B2 (en)	2003-03-14	2011-07-27	小野薬品工業株式会社	Nitrogen-containing heterocyclic derivatives and drugs containing them as active ingredients
US7122557B2 (en)	2003-03-18	2006-10-17	Bristol-Myers Squibb Company	Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
US7429596B2 (en)	2003-06-20	2008-09-30	The Regents Of The University Of California	1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
US20100267778A1 (en)	2003-08-04	2010-10-21	Shinya Kusuda	Diphenyl ether compound, process for producing the same, and use
WO2005016349A1 (en)	2003-08-14	2005-02-24	Icos Corporation	Methods of inhibiting leukocyte accumulation
US20050043239A1 (en)	2003-08-14	2005-02-24	Jason Douangpanya	Methods of inhibiting immune responses stimulated by an endogenous factor
US20050239809A1 (en)	2004-01-08	2005-10-27	Watts Stephanie W	Methods for treating and preventing hypertension and hypertension-related disorders
ES2873875T3 (en)	2004-05-13	2021-11-04	Icos Corp	Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
CA2730540A1 (en)	2004-05-13	2005-12-01	Vanderbilt University	Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
WO2005117889A1 (en)	2004-05-25	2005-12-15	Icos Corporation	Methods for treating and/or preventing aberrant proliferation of hematopoietic
EP1750715A1 (en)	2004-06-04	2007-02-14	Icos Corporation	Methods for treating mast cell disorders
AU2005283326B2 (en)	2004-09-13	2011-07-21	Ono Pharmaceutical Co., Ltd.	Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
US20080287469A1 (en)	2005-02-17	2008-11-20	Diacovo Thomas G	Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
US20070063319A1 (en)	2005-09-19	2007-03-22	Bohumil Lojek	Film stack and method for fabricating the same
KR20090017498A (en)	2006-04-04	2009-02-18	더 리젠트스 오브 더 유니이버시티 오브 캘리포니아	PI3 kinase antagonist
SI2004654T1 (en) *	2006-04-04	2013-11-29	The Regents Of The University Of California	Pyrazolopyrimidine derivatives for use as kinase antagonists
MX2009000107A (en)	2006-06-29	2009-01-23	Schering Corp	Substituted bicyclic and tricyclic thrombin receptor antagonists.
EP2081892A4 (en)	2006-11-17	2014-03-05	Donald F Weaver	COMPOUNDS AND METHODS FOR TREATING PROTEIN FOLDING DISORDERS
WO2008067219A2 (en)	2006-11-29	2008-06-05	Kalypsys, Inc.	Quinazolinone modulators of tgr5
US8338437B2 (en)	2007-02-28	2012-12-25	Methylgene Inc.	Amines as small molecule inhibitors
WO2008140750A1 (en)	2007-05-10	2008-11-20	Hydra Biosciences Inc.	Compounds for modulating trpv3 function
WO2009088990A1 (en)	2008-01-04	2009-07-16	Intellikine, Inc.	Certain chemical entities, compositions and methods
CA2738429C (en)	2008-09-26	2016-10-25	Intellikine, Inc.	Heterocyclic kinase inhibitors
US20110269779A1 (en)	2008-11-18	2011-11-03	Intellikine, Inc.	Methods and compositions for treatment of ophthalmic conditions
AU2009322187B2 (en)	2008-12-04	2015-02-19	The United States Of America, As Represented By The Secretary, Department Of Health And Human Services	Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of CNS disorders
US8658648B2 (en)	2008-12-05	2014-02-25	Designmedix, Inc.	Modified chloroquines with single ring moiety or fused ring moiety
MX2011009955A (en) *	2009-03-24	2011-11-18	Gilead Calistoga Llc	Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use.
BR112012002331A2 (en)	2009-08-05	2019-09-24	Versitech Ltd	antiviral composition, pharmaceutical composition and use of effective amount of pharmaceutical composition
GB0918249D0 (en) *	2009-10-19	2009-12-02	Respivert Ltd	Compounds
UY33337A (en)	2010-10-18	2011-10-31	Respivert Ltd	SUBSTITUTED DERIVATIVES OF 1H-PIRAZOL [3,4-d] PYRIMIDINE AS INHIBITORS OF PHOSFOINOSITIDE 3-KINASES
SG11201404522VA (en)	2012-03-13	2014-10-30	Respivert Ltd	Crystalline pi3 kinase inhibitors
AR095353A1 (en) *	2013-03-15	2015-10-07	Respivert Ltd	COMPOUND

2014
- 2014-03-13 JO JOP/2014/0103A patent/JO3279B1/en active
- 2014-03-13 TW TW103108912A patent/TW201522341A/en unknown
- 2014-03-14 WO PCT/GB2014/050770 patent/WO2014140597A1/en not_active Ceased
- 2014-03-14 EP EP14712334.3A patent/EP2970293B1/en active Active
- 2014-03-14 MX MX2015012091A patent/MX2015012091A/en unknown
- 2014-03-14 SG SG11201505928YA patent/SG11201505928YA/en unknown
- 2014-03-14 CA CA2899812A patent/CA2899812A1/en not_active Abandoned
- 2014-03-14 BR BR112015019754A patent/BR112015019754A8/en not_active IP Right Cessation
- 2014-03-14 UY UY0001035446A patent/UY35446A/en unknown
- 2014-03-14 CN CN201480015955.2A patent/CN105229007B/en not_active Expired - Fee Related
- 2014-03-14 KR KR1020157023823A patent/KR20150127607A/en not_active Withdrawn
- 2014-03-14 EA EA201591804A patent/EA029218B1/en not_active IP Right Cessation
- 2014-03-14 JP JP2015562319A patent/JP6353856B2/en not_active Expired - Fee Related
- 2014-03-14 ES ES14712334.3T patent/ES2640624T3/en active Active
- 2014-03-14 UA UAA201507682A patent/UA116002C2/en unknown
- 2014-03-14 AU AU2014229768A patent/AU2014229768B2/en not_active Ceased
- 2014-03-14 US US14/777,021 patent/US9745306B2/en not_active Expired - Fee Related
- 2014-03-14 PE PE2015001926A patent/PE20151653A1/en not_active Application Discontinuation
2015
- 2015-07-21 IL IL240061A patent/IL240061A0/en unknown
- 2015-08-04 GT GT201500218A patent/GT201500218A/en unknown
- 2015-08-20 PH PH12015501836A patent/PH12015501836A1/en unknown
- 2015-09-11 CL CL2015002606A patent/CL2015002606A1/en unknown
- 2015-09-11 NI NI201500134A patent/NI201500134A/en unknown
2017
- 2017-07-27 US US15/661,279 patent/US20170334919A1/en not_active Abandoned

Also Published As

Publication number	Publication date
BR112015019754A2 (en)	2017-07-18
JP6353856B2 (en)	2018-07-04
BR112015019754A8 (en)	2019-11-12
PE20151653A1 (en)	2015-11-12
CN105229007A (en)	2016-01-06
GT201500218A (en)	2017-09-21
EP2970293A1 (en)	2016-01-20
EP2970293B1 (en)	2017-06-14
NI201500134A (en)	2016-01-06
UA116002C2 (en)	2018-01-25
WO2014140597A1 (en)	2014-09-18
JP2016510802A (en)	2016-04-11
TW201522341A (en)	2015-06-16
IL240061A0 (en)	2015-09-24
CN105229007B (en)	2017-08-25
AU2014229768B2 (en)	2018-01-04
EA029218B1 (en)	2018-02-28
UY35446A (en)	2014-09-30
PH12015501836A1 (en)	2015-11-09
HK1214591A1 (en)	2016-07-29
CL2015002606A1 (en)	2016-03-04
US20170334919A1 (en)	2017-11-23
AU2014229768A1 (en)	2015-08-06
EA201591804A1 (en)	2016-01-29
KR20150127607A (en)	2015-11-17
US9745306B2 (en)	2017-08-29
ES2640624T3 (en)	2017-11-03
CA2899812A1 (en)	2014-09-18
MX2015012091A (en)	2016-04-15
US20160039826A1 (en)	2016-02-11
JO3279B1 (en)	2018-09-16

Publication	Publication Date	Title
IL240061A0 (en)	2015-09-24	2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1 -yl)methyl)-3-(2-(trifluoromet hyl)benzyl)quinazolin-4(3h)-one derivatives and their use as phosphoinositide 3-kinase inhibitors
IL246564A (en)	2016-11-30	3-aryl-1-heterocyclyl-pyrazolo[3,4-d]pyrimidine derivatives and use thereof in the treatment of diseases
IL264402B (en)	2019-09-26	Pyrrolo[3,2-d]pyrimidine derivatives for the treatment of viral infections and other diseases
SI3873884T1 (en)	2025-04-30	3-(quinolin-8-yl)-1,4-dihydropyrido[3,4-d]pyrimidin-2,4-dione derivatives as alpha4beta7 integrin inhibitors for the treatment of inflammatory diseases
BR112014028395A2 (en)	2017-06-27	substituted 3,4-dihydro-2h-pyrido [1,2-a] pyrazine-1,6-dione derivatives useful for the treatment of (inter alia) alzheimer's disease
EP3172214A4 (en)	2018-02-07	2-amino-pyrido[2,3-d]pyrimidin-7(8h)-one derivatives as cdk inhibitors and uses thereof
HUE061909T2 (en)	2023-08-28	Use of pyrazolo[1,5-a]pyrimidines as ATR kinase inhibitors for the treatment of cancer
IL237761B (en)	2018-12-31	Pyrrolo[3.2-d] pyrimidine derivatives for the treatment of viral infections and other diseases
IL254224A0 (en)	2017-10-31	7-substituted-5-alkyl-[1,2,4] triazolo[1,5-a]pyrimidine derivatives as pde2 inhibitors
EP3305785A4 (en)	2018-11-21	PYRIDO[3,4-d]PYRIMIDINE DERIVATIVE AND PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
AP2013007045A0 (en)	2013-08-31	6-Cyclobutyl-1,5-dihydro-pyrazolo[3,4-D] pyrimidin-4-one derivatives their use as PDE9A inhibitors
IL255901B (en)	2020-07-30	Crystal of (6s,9as)-n-benzyl-8-({6-[3-(4-ethylpiperazin-1-yl)azetidin-1-yl]pyridin-2-yl}methyl)-6-(2-fluoro-4-hyfroxybenzyl)-4,7-dioxo-2-(prop-2-en-1-yl)hexahydro-2h-pyrazino[2,1-c][1,2,4]triazine-1(6h)-carboxamide
HUE057549T2 (en)	2022-05-28	Imidazo [1,2-a] pyrimidine derivatives, process for their preparation and their use
TWI799399B (en)	2023-04-21	Pyrido[3,4-d]pyrimidine derivatives and pharmaceutically acceptable salts thereof
HRP20182021T1 (en)	2019-01-25	[1,2,4] TRIAZOLO [1,5-A] PYRIMIDINE DERIVATIVES AS PROTOZOMA PROTEOSOMA INHIBITORS FOR THE TREATMENT OF PARASITIC DISEASES LIKE LYMENIASIS
IL250104B (en)	2018-10-31	[1,2,4]triazolo[4,3-b]pyridazines for use in the treatment of proliferative diseases
MA46937A (en)	2019-10-09	3-AMINO-1,5-DIHYDRO-PYRAZOLO [3,4-D] PYRIMIDIN-4-ONES AS CYCLINE-DEPENDENT KINASE INHIBITORS
PL3842436T3 (en)	2024-03-04	Pharmaceutical compositions comprising imidazopyrimidine or imidazotriazine derivatives for use in the treatment of schizophrenia
ZA201808361B (en)	2019-08-28	Benzoxazine or quinazoline derivatives for use in the treatment of alzheimer¿s disease
TH1501005522A (en)	2017-08-10	Derivative 2-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4-D]pyrimidine- 1-yl)methyl)-3-(2-trifluoromethyl)benzyl)quinazolin-4(3H)-one and the use of these substances as phosphoinositide 3-kinase inhibitors.
IL253427A0 (en)	2017-09-28	Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
HK1238643A1 (en)	2018-05-04	Pyrazolo[3,4-d]pyrimidin derivative and its use for the treatment of leishmaniasis
HK40027828B (en)	2023-10-13	Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders
TH1501007226A (en)	2018-01-04	The compound 6,7-dihydropyrazolo[1,5-a]pyrazine-4(5H)-one and its use as an allosteric inhibitor of mGluR2. Sector
TH1601001194A (en)	2017-10-19	New triazolo[4,5-d]pyrimidine derivatives